Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 46, 1170-1175, March 1, 1986]
© 1986 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smolarek, T. A.
Right arrow Articles by Baird, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smolarek, T. A.
Right arrow Articles by Baird, W. M.

Benzo(e)pyrene-induced Alterations in the Stereoselectivity of Activation of 7,12-Dimethylbenz(a)anthracene to DNA-binding Metabolites in Hamster Embryo Cell Cultures1

Teresa A. Smolarek and William M. Baird2

Department of Medicinal Chemistry and Pharmacognosy, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907

Benzo(e)pyrene [B(e)P], a weakly carcinogenic polycyclic aromatic hydrocarbon, modifies tumor induction in mouse skin and the induction of mutation in mammalian cells by carcinogenic hydrocarbons. To determine how B(e)P alters the activation of the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) to DNA-binding metabolites, the hydrocarbon-DNA adducts formed in Syrian hamster embryo cell cultures were analyzed after 24, 48, or 72 h of exposure to 0.1 µg DMBA/ml medium in the presence of various doses of B(e)P. The total binding of DMBA to DNA was inhibited 3- to 4-fold by high doses of B(e)P, while the binding of DMBA to DNA was increased by low doses of B(e)P at 48 and 72 h of exposure. The amounts of the three major adducts tentatively identified as anti-DMBA-3,4-diol-1,2-epoxide (DMBADE): deoxyguanosine, syn - DMBADE: deoxyadenosine (dAdo), and anti-DMBADE:dAdo decreased in the presence of 1.5 µg B(e)P/ml. In contrast, exposure to low doses of B(e)P, 0.1 and 0.3 µg/ml medium, resulted in an increase in the amount of both anti-DMBADE:deoxyribonucleoside adducts and a decrease in the amount of syn-DMBADE:deoxyribonucleoside adduct present after 48 and 72 h of exposure. Thus, low doses of B(e)P specifically enhanced the formation of anti-DMBA-diolepoxide:deoxyribonucleoside adducts, and this resulted in an increase in the total amount of DMBA bound to DNA. High doses of B(e)P resulted in a decrease in the formation of all DMBA:DNA adducts and consequently a decrease in the total binding of DMBA to DNA. The amount of DMBA bound to DNA in cultures exposed to a higher dose of DMBA, 0.2 µg DMBA/ml medium, for 48 h decreased in the presence of both low and high concentrations of B(e)P. This decrease resulted from a reduction in the formation of all three major DMBA-DNA adducts as the dose of B(e)P increased, but the decrease was larger for the syn-DMBADE:dAdo adduct than for the anti-DMBADE:deoxyguanosine and :dAdo adducts. These results demonstrate that the effects of B(e)P on the metabolic activation of DMBA depend upon both the ratio of B(e)P:DMBA and the dose of DMBA. The ability of B(e)P to alter the stereochemical selectivity of activation of DMBA as well as the total amount of activated metabolites also suggests that the ratio of B(e)P:DMBA may be an important factor in B(e)P-induced modifications of the induction of biological effects by DMBA.

1 This work was supported by grant CA-28825 from the National Cancer Institute, Department of Health and Human Services.

2 To whom requests for reprints should be addressed.

Received 8/26/85. Revised 11/18/85. Accepted 11/20/85.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1986 by the American Association for Cancer Research.